At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 52 enrolled
Drug / intervention
ReSTORdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Outcomes With AcrySof ReSTOR Aspheric Apodized Diffractive Intraocular Lens (IOL) in One Eye and a Contralateral Monofocal IOL or Phakic Eye
In Brief
A Phase 4 clinical trial evaluating ReSTOR for Cataracts. Completed, enrolled 52 participants across 1 site.
Detailed Summary
Bilateral evaluation of unilateral implantation of ReSTOR and contralateral monofocal or phakic eye.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataracts
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
Primary CompletionMay 2008
First PostedAug 2008
TodayJul 2026
First PostedAug 11, 2008
Enrollment StartJun 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.9 years ago
Interventions
ReSTORdevice
AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted